Thread by @szusmani

I have been asked several questions about the #ASCO23 abstract:  
Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study (8034), wanted to create a 🧵 for #mmsm… twitter.com/i/web/status/1…

What were the criteria for switching to less frequent dosing schedules?
• In phase 1, patients had the option to switch from weekly to Q2W (every other week) dosing if they had achieved at least a partial response and at least 4 cycles of treatment
• In phase 2, patients had… twitter.com/i/web/status/1…

Given the rapid and deep responses, why did so many patients not switch (41/104 responders) to the less frequent dosing schedule?
• Switching was not mandated, but optional, for any patient who met the response criteria. This, in addition to the requirement for patients to… twitter.com/i/web/status/1…

How did efficacy compare for patients who switched to less frequent dosing vs those who remained on weekly dosing?
• Comparative efficacy analyses have not been performed, as data may be biased since all patients who switched were required to have responded; however, most… twitter.com/i/web/status/1…